

Title: Clinical Holds in Early Oncology Drug Development

Authors: Alexandra Snyder\* MD, Dinesh De Alwis, PhD, Asthika Goonewardene, Priti S. Hegde\* PhD

\*Co-corresponding

Affiliation and contacts

AS: Two River, Inc. 689 Fifth Ave, New York, NY 10022

AG: Truist Securities. 711 Fifth Ave, New York, NY 10022

DD: Early Oncology Development, Merck & Co., Inc., Rahway, NJ, USA

PSH: Foundation Medicine. 150 Second Street, Cambridge, MA 02141

## Abstract

Clinical holds in oncology are necessary to safeguard patients. Researchers are alerted to holds by news sources, but a systematic evaluation of clinical holds in early oncology drug development is lacking. Analysis of publicly disclosed clinical holds in oncology from 2016-2021 identified 39 holds. The majority (n=29) were for toxicity-related reasons, with fewer for chemistry, manufacturing and controls (CMC) (n=7) or other reasons (n=3). Toxicity-related holds took a median of 74 days till resolution, whereas chemistry, manufacturing and controls (CMC)-related holds took a median of 108 days to resolve. Acknowledging the limited sample size and scope of stock market conditions, toxicity-related clinical holds impacted the market value of small/medium sized biotechs by a median of -15%, which is far more than large biopharma (median 0%). These data suggest that toxicity-related clinical holds are common in early oncology and can have a more detrimental impact on small/medium sized biotech sponsors, the latter of which could have substantial financial repercussions, particularly in “biotech bear markets” where public investing in the sector has fallen out of favor (as in 2021-2022).

Text:

Development of novel oncology drugs and platforms now occurs primarily in the context of smaller biotechnology companies. In the years 2020-21, 36% of oncology drug approvals by the US FDA were of drugs developed by a biotech company and 64% by big pharma (Supplementary Table S1). Importantly, a large majority of approvals for big pharma constituted label expansions, whereas 100% of approvals for small biotech were related to novel therapies or platforms<sup>1</sup>.

Indeed, approximately 80% of the overall industry pipeline comes from emerging biopharma companies<sup>2</sup>. Of the 112 oncology drug approvals in 2020-2021, 40 were of drugs developed by small biotechs. Of these 40, based on company disclosures, 9 were put on partial or full clinical hold at some point in their development. Such holds have at times led to a dramatic drop in public interest in a biotech, despite evidence of efficacy (Fig. 1A).

Chimeric antigen receptor (CAR) therapies provide an example of platform development that has benefited from time spent in understanding clinical safety, including revisions caused by clinical holds. CARs outfit T cells and other immune cell types with receptors that can attack cancer and have now become standard of care for the treatment of some patients with lymphoma and multiple myeloma. However, their development path has featured pauses and redirections, as these drugs can lead to substantial systemic inflammation, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). A study of a CD19 CAR-T therapy, JCAR015, was put on hold in 2016 due to 3 patient deaths out of 20 accrued patients. Initially, fludarabine, a drug used to condition the body prior to the experimental therapy, was faulted. However, after an additional 2 patients died, the trial was put on hold indefinitely and the sponsor, Juno, shifted development to JCAR017, an optimized CAR-T drug that also targeted CD19 but with different viral vector, binding domain, costimulatory domain and T-cell selection process. Juno lost \$1.36B in market cap when they announced the first clinical hold in July 2016, and \$1.39B when they announced the second hold in November 2016 (Supplementary Fig. S1), although it bears noting that other fluctuations occurred in the stock price outside of these events. The optimized agent, JCAR017, was ultimately approved by the FDA for treatment of lymphomas<sup>3</sup>; this success, among other variables, has spawned vigorous development and optimization in the cell therapy space.

To identify larger trends in the field, as there is no repository of clinical holds in early oncology, we surveyed press releases and public investor call transcripts with the words “clinical hold” available on Bloomberg from 2016 to 2021 for US-based companies (Table 1). 39 oncology-

related holds occurred during this period. Of these, among the 29 toxicity-related holds, 10 were for cell therapies, 6 for T-cell engagers (TCE), 5 for antibodies in immuno-oncology, 4 for antibody-drug conjugates and 4 for small molecules. 18 were resolved, 6 were terminated and 5 were ongoing as of this writing. Seven holds were for reasons related to chemistry, manufacturing and controls (CMC): 3 for cell therapies, 1 for TCE and 3 for IO, all of which were resolved. Three holds were for other reasons. Toxicity-related holds took a median of 74 days till resolution irrespective of the platform (with immuno-oncology (IO) agents an outlier at 100 days median) (Table 1B), whereas CMC-related holds took a median of 108 days to resolve.

Acknowledging the limited sample size, clinical holds impacted the market value of small/medium sized biotechs more than large biopharma (Table 1C). The rebound after hold removal was greater for CMC-related holds than safety-related holds (Fig. 1B). We hypothesize that this contrast may be because, despite hold resolution, toxicities become part of the risk:benefit profile of the agent, impacting the drug profile beyond the hold.

Some limitations of our methodology include:

- We were only able to capture clinical holds that were publicly disclosed in a press release or on an investor call; a clinical hold may not be material enough for a large biopharma company to issue a press release, so we may be undercounting clinical holds experienced by larger companies.
- We were only able to capture companies that continued to exist; therefore, our survey likely underestimates the impact of clinical holds on the fate of biotech companies.
- Our analysis of share price reactions accounts for the absolute change in share price, but does not account for the relative movement versus the broader stock market or relevant indices, nor does it account for investor sentiment that is already baked into the share price. Our analysis of events was restricted to 2016-2021, and this represents a period of more favorable market conditions for biotech investing. In more recent times (2021-to date), biotech has been in a “bear market” where long term public market investing has fallen out of favor. In these conditions, negative share price movements due to clinical holds can be exacerbated.

Technological breakthroughs paired with ongoing clinical need make oncology a fertile space for drug development. Such development is attended by myriad risks, including to the safety of patients treated on clinical trials, and requires the consistent production of high quality drug products. Clinical holds are a necessary part of drug development intended to protect

patient safety. Historical examples (described in an upcoming publication by Snyder et al.<sup>4</sup>) demonstrate that careful optimization of oncology drugs can lead to the development of therapies that improve and prolong lives; Project Optimus, an FDA initiative start in 2022 to improve dose-finding in oncology, underscores the need for methodical early drug development. While qualitative in nature, data described here suggest that clinical holds, whether for toxicity or CMC, do not necessarily hinder likelihood of eventual drug approval, and may result in better therapeutics. However, such events can cause a significant drop in investor interest, particularly for small biotechnology companies. While such fluctuations are a natural part of drug development, this analysis suggests that a careful examination of each case may be instructive, informing the field whether actions taken as a result of the hold may in fact lead to an approval-worthy drug profile.

## References

1. Oncology (Cancer)/Hematologic Malignancies Approval Notification. (2022).
2. Investment in Biopharma is Reaching an Inflection Point. (2021).
3. Abramson, J.S., *et al.* Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. *Lancet* **396**, 839-852 (2020).
4. Snyder, A. Balancing Speed, Science and Regulatory Requirements in Oncology Drug Development. Under review, (2022).

Disclosures:

AS is an employee of Two River, Inc and owns shares in Allogene Therapeutics and Merck & Co., Inc., Rahway, NJ, USA.

PSH is an employee of Foundation Medicine, Inc and owns shares in Roche, Bolt Therapeutics and TCR2.

DD is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and owns shares in Merck & Co., Inc., Rahway, NJ, USA.

Figures and Tables Associated with Clinical Holds in Early Oncology Drug Development

Authors: Alexandra Snyder MD, Dinesh De Alwis, PhD, Asthika Goonewardene, Priti Hegde PhD




Figure 1A. Share Price Reaction to Clinical Hold Announcement - SMID Biotech

This chart represents the share price movement on the day of or day after a clinical hold was first reported, against the prior 3 day rolling average. The X axis indicates the company and the date the hold was announced. Dark purple bars represent share price reactions for clinical holds due to toxicity, light purple bars represent clinical holds due to CMC issues, and gray bars represent clinical holds due to other reasons (PK/PD, trial disclosures, etc.). Dotted lines represent median share price reaction to clinical holds due to toxicity (dark purple) or CMC (light purple). In this chart, only SMID- cap biotech companies' share price reactions and medians are represented. SMID=small and medium cap biotechs, here defined as value less than \$10B. Large cap defined as value greater than or equal to \$10 billion.






Figure 1B. Share Price Reaction to Clinical Hold Resolution - SMID Biotech

This chart represents the share price movement on the day of or day after a clinical hold was reported as successfully resolved, against the prior 3 day rolling average. The X axis indicates the company and the date the resolution was announced. Dark purple bars represent share price reactions for clinical holds due to toxicity, light purple bars represent clinical holds due to CMC issues, and gray bars represent clinical holds due to other reasons (PK/PD, trial disclosures, etc.). Dotted lines represent median share price reaction to resolving clinical holds due to toxicity (dark purple) or CMC (light purple). In this chart, only SMID-cap biotech companies' share price reactions and medians are represented.

Table 1A. Mechanisms and outcomes of clinical holds in oncology, 2016-2021. CMC = chemistry, manufacturing and controls.

<b>Breakdown Of The Clinical Holds Considered</b>									
	<b>Total</b>	<b>Mechanism of Action</b>					<b>Outcome</b>		
		Cell Tx	Imm Engagers & Other bsAbs	IO	Conj	Small Mol	Resolved	Terminated	Ongoing
Toxicity	29	10	6	5	4	4	18	6	5
CMC	7	3	1	3	0	0	7	0	0
Other	3						2		1
<b>Total</b>	<b>39</b>						<b>27</b>	<b>6</b>	<b>6</b>


Table 1B. Median time to resolution of clinical holds, 2016-2021.

<b><u>Time To Resolve Clinical Holds (Days)</u></b>	
<b>Reason for Hold: Toxicity or Patient Death</b>	<b>74</b>
<i>Cell Therapy</i>	71
<i>Immune Engagers &amp; Other Bispecific Antibodies</i>	69
<i>Immuno-Oncology</i>	100
<i>Conjugates</i>	65
<b>Reason for Hold: CMC</b>	<b>108</b>
<i>Cell Therapy</i>	98

Table 1C. Median share price moves relative to hold announcement, 2016-2021.

<b>Median Share Price Moves (On Announcement vs Prior 3 Day Average)</b>			
	<b>All companies</b>	<b>SMID-cap</b>	<b>Large-cap</b>
<b>Clinical Hold Announced</b>			
<i>Reason for Hold: Toxicity or Patient Death</i>	<b>-11%</b>	<b>-15%</b>	<b>0%</b>
<i>Reason for Hold: CMC</i>	<b>-6%</b>	<b>-6%</b>	
<b>Clinical Hold Successfully Resolved</b>			
<i>Reason for Hold: Toxicity or Patient Death</i>	<b>-1%</b>	<b>-1%</b>	<b>-1%</b>
<i>Reason for Hold: CMC</i>	<b>4%</b>	<b>4%</b>	
<b>Clinical Hold Leads To Asset Termination</b>			
<i>Reason for Hold: Toxicity or Patient Death</i>	<b>-8%</b>	<b>-8%</b>	

Supplementary Figure S1. Juno stock price by date and key events, 2016-2018. Source: Bloomberg.



**Supplementary Table S1. Oncology Approvals by the US FDA, 2020-2021**

Approval	Description	Date
FDA approves abatacept for prophylaxis of acute graft versus host disease	On December 15, 2021, the Food and Drug Administration approved abatacept (Orencia, Bristol-Myers Squibb Company) for the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor (CNI) and methotrexate (MTX), in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor.	12/15/2021
FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma	On December 3, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) for the adjuvant treatment of adult and pediatric (≥12 years of age) patients with stage IIB or IIC melanoma following complete resection.	12/3/2021
FDA approves rituximab plus chemotherapy for pediatric cancer indications	On December 2, 2021, the Food and Drug Administration approved rituximab (Rituxan, Genentech, Inc.) in combination with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).	12/2/2021
FDA approves Darzalex Faspro, Kyprolis, and Dexamethasone for Multiple Myeloma	On November 30, 2021, the Food and Drug Administration approved daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen, Inc.) plus dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.	12/01/2021
FDA approves pafolacianine for identifying malignant ovarian cancer lesions	On November 29, 2021, the Food and Drug Administration approved pafolacianine (Cytalux, On Target Laboratories, LLC), an optical imaging agent, for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Pafolacianine is a fluorescent drug that targets folate receptor which may be overexpressed in ovarian cancer. It is used with a Near-Infrared (NIR) fluorescence imaging system cleared by the FDA for specific use with pafolacianine.	11/29/2021
FDA approves sirolimus protein-bound particles for malignant perivascular epithelioid cell tumor	On November 22, 2021, the Food and Drug Administration approved sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro, Aadi Bioscience, Inc.) for adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).	11/23/2021

FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma	On November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.	11/17/2021
FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia	On October 29, 2021, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), and approved asciminib for adult patients with Ph+ CML in CP with the T315I mutation.	10/29/2021
FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer	On October 15, 2021, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on $\geq 1\%$ of tumor cells, as determined by an FDA-approved test.	10/15/2021
FDA approves pembrolizumab combination for the first-line treatment of cervical cancer	On October 13, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS $\geq 1$ ), as determined by an FDA- approved test.	10/13/2021
FDA approves abemaciclib with endocrine therapy for early breast cancer	On October 12, 2021, the Food and Drug Administration approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score $\geq 20\%$ , as determined by an FDA approved test. This is the first CDK 4/6 inhibitor approved for adjuvant treatment of breast cancer.	10/12/2021
FDA approves brexucabtagene autoleucl for relapsed or refractory B-cell precursor acute lymphoblastic leukemia	On October 1, 2021, the Food and Drug Administration approved brexucabtagene autoleucl (Tecartus, Kite Pharma, Inc.) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).	10/1/2021
FDA approves ruxolitinib for chronic graft-versus host disease	On September 22, 2021, the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte Corp.) for chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.	9/22/2021

FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer	On September 20, 2021, the Food and Drug Administration granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.	9/20/2021
FDA approves cabozantinib for differentiated thyroid cancer	On September 17, 2021, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine.	9/17/2021
FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations	Food and Drug Administration granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.	9/15/2021
FDA grants accelerated approval to zanubrutinib for marginal zone lymphoma	Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.	9/14/2021
FDA approves zanubrutinib for Waldenström's macroglobulinemia	Food and Drug Administration approved zanubrutinib (Brukinsa, BeiGene) for adult patients with Waldenström's macroglobulinemia (WM).	9/1/2021
FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma	Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.	8/25/2021
FDA approves nivolumab for adjuvant treatment of urothelial carcinoma	Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Co.) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection.	8/19/2021



FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors	Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.	8/18/2021
FDA approves belzutifan for cancers associated with von Hippel-Lindau disease	Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc., Rahway, NJ, USA), a hypoxia-inducible factor inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery	8/13/2021
FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma	Food and Drug Administration approved the combination of lenvatinib (Lenvima, Eisai) plus pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC).	8/10/2021
FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer	Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.	7/26/2021
FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma	Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) in combination with lenvatinib (Lenvima, Eisai) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.	7/21/2021
FDA approves belumosudil for chronic graft-versus-host disease	Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.	7/16/2021
FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma	Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.	7/9/2021

FDA grants regular approval to enfortumab vedotin-ejfv for locally advanced or metastatic urothelial cancer	Food and Drug Administration approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), a Nectin-4-directed antibody and microtubule inhibitor conjugate, for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand (PD-L1) inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.	7/9/2021
FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukemia and lymphoma	Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze, Jazz Pharmaceuticals, Inc.) as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase. .	7/1/2021
FDA approves avapritinib for advanced systemic mastocytosis	Food and Drug Administration approved avapritinib (Ayvakit™, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).	6/16/2021
FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma	Food and Drug Administration granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.), a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test	5/28/2021
FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC	Food and Drug Administration granted accelerated approval to sotorasib (Lumakras™, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.	5/28/2021
FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer	FDA granted accelerated approval to amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.	5/21/2021

FDA approves nivolumab for resected esophageal or GEJ cancer	Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy.	5/20/2021
FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer	Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.	5/5/2021
FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma	On April 23, 2021, the Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.	4/23/2021
FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer	Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen.	4/22/2021
FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma	Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.	4/16/2021
FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer	FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer.	4/13/2021

<p>FDA grants regular approval to sacituzumab for triple-negative breast cancer</p>	<p>Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.</p>	<p>4/7/2021</p>
<p>FDA approves new dosing regimen for cetuximab</p>	<p>Food and Drug Administration approved a new dosage regimen of 500 mg/m<sup>2</sup> as a 120-minute intravenous infusion every two weeks (Q2W) for cetuximab (Erbix, ImClone LLC) for patients with K-Ras wild-type, EGFR-expressing colorectal cancer (mCRC) or squamous cell carcinoma of the head and neck (SCCHN).</p>	<p>4/6/2021</p>
<p>FDA approves isatuximab-irfc for multiple myeloma</p>	<p>Food and Drug Administration approved isatuximab-irfc (Sarclisa, sanofi-aventis U.S. LLC) in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. March 31, 2021</p>	<p>3/31/2021</p>
<p>FDA approves idecabtagene vicleucel for multiple myeloma</p>	<p>Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma. March 26, 2021</p>	<p>3/26/2021</p>
<p>FDA approves pembrolizumab for esophageal or GEJ carcinoma</p>	<p>Food and Drug Administration approved pembrolizumab (Keytruda, Merck &amp; Co., Inc., Rahway, NJ, USA) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal (GEJ) (tumors with epicenter 1 to 5 centimeters above the gastroesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation. March 22, 2021.</p>	<p>3/22/2021</p>
<p>FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma</p>	<p>Food and Drug Administration approved tivozanib (Fotivda, AVEO Pharmaceuticals, Inc.), a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. March 10, 2021</p>	<p>3/10/2021</p>

FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma	Food and Drug Administration granted accelerated approval to axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.	3/5/2021
FDA approves lorlatinib for metastatic ALK-positive NSCLC	Food and Drug Administration granted regular approval to lorlatinib (Lorbrena, Pfizer Inc.) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, detected by an FDA-approved test. March 3, 2021	3/3/2021
FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma	Food and Drug Administration granted accelerated approval to melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody. Efficacy was evaluated in HORIZON (NCT02963493), a multicenter, single-arm trial. Eligible patients were required to have relapsed refractory multiple myeloma. Patients received melphalan flufenamide 40 mg intravenously on day 1 and dexamethasone 40 mg orally (20 mg for patients $\geq 75$ years of age) on day 1, 8, 15 and 22 of each 28-day cycle until disease progression or unacceptable toxicity.	2/26/2021
FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression	Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression (Tumor Proportion Score [TPS] > 50%) as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations.	2/22/2021
FDA approves cemiplimab-rwlc for locally advanced and metastatic basal cell carcinoma	Food and Drug Administration approved cemiplimab-rwlc for locally advanced and metastatic basal cell carcinoma.	2/9/2021

FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma	Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. February 5, 2021	2/5/2021
FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma	Food and Drug Administration granted accelerated approval to umbralisib (Ukoniq, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for the following indications: Adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen; Adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.	2/5/2021
FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer	Food and Drug Administration granted accelerated approval to tepotinib (Tepmetko, EMD Serono Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.	2/3/2021
FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma	Food and Drug Administration approved the combination of nivolumab (Opdivo, Bristol-Myers Squibb Co.) and cabozantinib (Cabometyx, Exelixis) as first-line treatment for patients with advanced renal cell carcinoma (RCC).	1/22/2021
FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis	Food and Drug Administration granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro, Janssen Biotech Inc.) in combination with bortezomib, cyclophosphamide and dexamethasone for newly diagnosed light chain (AL) amyloidosis.	1/15/2021
FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas	Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.	1/15/2021

<p>FDA approves crizotinib for children and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma</p>	<p>Food and Drug Administration approved crizotinib (Xalkori, Pfizer Inc.) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.</p>	<p>1/14/2021</p>
<p>FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations</p>	<p>Food and Drug Administration approved osimertinib (TAGRISSO, AstraZeneca Pharmaceuticals LP) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.</p>	<p>12/18/2020</p>
<p>FDA approves relugolix for advanced prostate cancer</p>	<p>Food and Drug Administration approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, (ORGOVYX, Myovant Sciences, Inc.) for adult patients with advanced prostate cancer.</p>	<p>12/18/2020</p>
<p>FDA approves selinexor for refractory or relapsed multiple myeloma</p>	<p>Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.</p>	<p>12/18/2020</p>
<p>FDA approves margetuximab for metastatic HER2-positive breast cancer</p>	<p>Food and Drug Administration approved margetuximab-cmkb (MARGENZA, MacroGenics) in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</p>	<p>12/16/2020</p>
<p>FDA approves pralsetinib for RET-altered thyroid cancers</p>	<p>Food and Drug Administration approved pralsetinib (GAVRETO, Blueprint Medicines Corporation) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).</p>	<p>12/1/2020</p>
<p>FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow</p>	<p>Food and Drug Administration granted accelerated approval to naxitamab (DANYELZA, Y-mAbs Therapeutics, Inc.) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy.</p>	<p>11/25/2020</p>

<p>FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer</p>	<p>Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck &amp; Co., Inc., Rahway, NJ, USA) in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS <math>\geq</math>10) as determined by an FDA approved test.</p>	<p>11/13/2020</p>
<p>FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia</p>	<p>Food and Drug Administration grants regular approval to venetoclax in combination for untreated acute myeloid leukemia.</p>	<p>10/16/2020</p>
<p>FDA extends approval of pembrolizumab for classical Hodgkin lymphoma</p>	<p>Food and Drug Administration extended the approval of pembrolizumab (KEYTRUDA®, Merck &amp; Co., Inc., Rahway, NJ, USA) for the following indications: adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.</p>	<p>10/14/2020</p>
<p>FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma</p>	<p>Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) as first-line treatment for adult patients with unresectable malignant pleural mesothelioma.</p>	<p>10/2/2020</p>
<p>FDA approves pralsetinib for lung cancer with RET gene fusions</p>	<p>Food and Drug Administration granted accelerated approval to pralsetinib (GAVRETO, Blueprint Medicines Corporation) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.</p>	<p>9/4/2020</p>
<p>FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia</p>	<p>Food and Drug Administration approved azacitidine tablets (ONUREG, Celgene Corporation) for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.</p>	<p>9/1/2020</p>
<p>FDA approves carfilzomib and daratumumab with dexamethasone for multiple myeloma</p>	<p>On August 20, 2020, the Food and Drug Administration approved carfilzomib (KYPROLIS, Onyx Pharmaceuticals, Inc.) and daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.</p>	<p>8/20/2020</p>



FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma	Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.	8/5/2020
FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma	FDA granted accelerated approval to tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, indicated in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.	7/31/2020
FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma	Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.	7/30/2020
FDA approves brexucabtagene autoleucl for relapsed or refractory mantle cell lymphoma	Food and Drug Administration granted accelerated approval to brexucabtagene autoleucl (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).	7/24/2020
FDA approves oral combination of decitabine and cedazuridine for myelodysplastic syndromes	Food and Drug Administration approved an oral combination of decitabine and cedazuridine (INQOVI, Astex Pharmaceuticals, Inc.) for adult patients with myelodysplastic syndromes (MDS) including the following:	7/7/2020
FDA approves avelumab for urothelial carcinoma maintenance treatment	Food and Drug Administration approved avelumab (BAVENCIO, EMD Serono, Inc.) for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.	6/30/2020
FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer	Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co., Inc., Rahway, NJ, USA) for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. June 29, 2020	6/29/2020

FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer	Food and Drug Administration approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO, Genentech, Inc.) for subcutaneous injection	6/29/2020
FDA approves pembrolizumab for cutaneous squamous cell carcinoma	Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co., Inc., Rahway, NJ, USA) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation	6/24/2020
FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma	Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.	6/22/2020
FDA granted accelerated approval to tazemetostat for follicular lymphoma	Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.), an EZH2 inhibitor, for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	6/18/2020
FDA approves pembrolizumab for adults and children with TMB-H solid tumors	Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc., Rahway, NJ, USA) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [ $\geq 10$ mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.	6/16/2020
FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients	Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARG, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients 1 month and older.	6/16/2020
FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer	Food and Drug Administration granted accelerated approval to lurbinectedin (ZEPZELCA, Pharma Mar S.A.) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. June 15, 2020	6/15/2020

FDA approves nivolumab for esophageal squamous cell carcinoma	Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.	6/10/2020
FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC	Food and Drug Administration approved ramucirumab (CYRAMZA, Eli Lilly and Company) in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.	5/29/2020
FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma	Food and Drug Administration approved atezolizumab in combination with bevacizumab (TECENTRIQ and AVASTIN, Genentech Inc.) for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.	5/29/2020
FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC	Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.	5/26/2020
FDA approves brigatinib for ALK-positive metastatic NSCLC	Food and Drug Administration approved brigatinib (ALUNBRIG, ARIAD Pharmaceuticals Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.	5/22/2020
FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer	Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	5/19/2020
FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression	Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained $\geq 50\%$ of tumor cells [TC $\geq 50\%$ ] or PD-L1 stained tumor-infiltrating immune cells [IC] covering $\geq 10\%$ of the tumor area [IC $\geq 10\%$ ]), with no EGFR or ALK genomic tumor aberrations. May 18, 2020	5/18/2020

FDA approves ripretinib for advanced gastrointestinal stromal tumor

Food and Drug Administration approved ripretinib (QINLOCK, Deciphera Pharmaceuticals, LLC.), for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

5/15/2020

FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer

Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.

5/15/2020

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression  $\geq 1\%$ )

Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1 ( $\geq 1\%$ ), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

5/15/2020

FDA grants accelerated approval to pomalidomide for Kaposi sarcoma

Food and Drug Administration expanded the indication of pomalidomide (POMALYST, Celgene Corporation) to include treating adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative.

5/14/2020

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

Food and Drug Administration expanded the indication of olaparib (LYNPARZA<sup>®</sup>, AstraZeneca Pharmaceuticals, LP) to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.

5/8/2020

<p>FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions</p>	<p>Food and Drug Administration granted accelerated approval to selpercatinib (RETEVMO, Eli Lilly and Company) for the following indications: Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC); Adult and pediatric patients <math>\geq 12</math> years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; Adult and pediatric patients <math>\geq 12</math> years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).</p>	<p>5/8/2020</p>
<p>FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer</p>	<p>Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.</p>	<p>5/6/2020</p>
<p>FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma</p>	<p>Food and Drug Administration approved daratumumab and hyaluronidase-fihj (DARZALEX FASPRO, Janssen Biotech, Inc.) for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. This new product allows for subcutaneous dosing of daratumumab. May 1, 2020</p>	<p>5/1/2020</p>
<p>FDA approves niraparib for first-line maintenance of advanced ovarian cancer</p>	<p>Food and Drug Administration approved niraparib (Zejula, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.</p>	<p>4/29/2020</p>
<p>FDA approves new dosing regimen for pembrolizumab</p>	<p>Food and Drug Administration granted accelerated approval to a new dosing regimen of 400 mg every six weeks for pembrolizumab (KEYTRUDA, Merck &amp; Co., Inc., Rahway, NJ, USA) across all currently approved adult indications, in addition to the current 200 mg every three weeks dosing regimen.</p>	<p>4/28/2020</p>
<p>FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer</p>	<p>Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY, Immunomedics, Inc.) for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease.</p>	<p>4/22/2020</p>

FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia	Food and Drug Administration expanded the indication of ibrutinib (IMBRUVICA, Pharmacyclics LLC) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).	4/21/2020
FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion	Food and Drug Administration granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.	4/20/2020
FDA approves tucatinib for patients with HER2-positive metastatic breast cancer	Food and Drug Administration approved tucatinib (TUKYSA, Seattle Genetics, Inc.) in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.	4/17/2020
FDA approves mitomycin for low-grade upper tract urothelial cancer	Food and Drug Administration approved mitomycin (JELMYTO™, UroGen Pharma) for adult patients with low-grade upper tract urothelial cancer (LG-UTUC).	4/15/2020
FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas	Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca) for pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).	4/10/2020
FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation	Food and Drug Administration approved encorafenib (BRAFTOVI, Array BioPharma Inc.) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy.	4/8/2020

FDA approves luspatercept-aamt for anemia in adults with MDS	Food and Drug Administration approved luspatercept-aamt (REBLOZYL, Celgene Corporation) for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).	4/3/2020
FDA approves durvalumab for extensive-stage small cell lung cancer	Food and Drug Administration approved durvalumab (IMFINZI, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).	3/30/2020
FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma	Food and Drug Administration granted accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY, Bristol-Myers Squibb Co.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.	3/10/2020
FDA approves isatuximab-irfc for multiple myeloma	Food and Drug Administration approved isatuximab-irfc (SARCLISA, sanofi-aventis U.S. LLC) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.	3/2/2020
FDA approves neratinib for metastatic HER2-positive breast cancer	Food and Drug Administration approved neratinib (NERLYNX, Puma Biotechnology, Inc.) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.	2/25/2020
FDA approves tazemetostat for advanced epithelioid sarcoma	Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.	1/23/2020
FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation	Food and Drug Administration approved avapritinib (AYVAKIT, Blueprint Medicines Corporation) for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V mutations.	1/9/2020

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer	Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co., Inc., Rahway, NJ, USA) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.	1/8/2020
---	--	----------